Rigel Pharmaceuticals (RIGL) Shares Outstanding (Weighted Average) (2010 - 2026)

Rigel Pharmaceuticals has reported Shares Outstanding (Weighted Average) for 17 years, with the latest figure at $18.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 3.39% year-over-year to $18.4 million; the trailing twelve-month figure through Mar 2026 stood at $18.4 million (up 3.39% YoY), and the FY2025 full-year result was $18.0 million, up 2.32% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $18.4 million, up from $18.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $173.6 million in Q1 2023, with the low at $17.0 million in Q4 2022.
• Average Shares Outstanding (Weighted Average) over 5 years is $54.1 million, with a median of $17.8 million recorded in 2025.
• Year-over-year, Shares Outstanding (Weighted Average) plunged 90.0% in 2022 and rose 3.39% in 2026.
• Tracing RIGL's Shares Outstanding (Weighted Average) over 5 years: stood at $17.0 million in 2022, then increased by 2.06% to $17.4 million in 2023, then grew by 1.02% to $17.6 million in 2024, then gained by 2.32% to $18.0 million in 2025, then gained by 2.36% to $18.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $18.4 million (Q1 2026), $18.0 million (Q4 2025), and $18.0 million (Q3 2025), per Business Quant data.

Peer Comparison